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Mitochondrial production of ROS (reactive oxygen species) is
thought to be associated with the cellular damage resulting from
chronic exposure to high glucose in long-term diabetic patients.
We hypothesized that a mitochondria-targeted antioxidant would
prevent kidney damage in the Ins2
+/−AkitaJ mouse model (Akita
mice) of Type 1 diabetes. To test this we orally administered
a mitochondria-targeted ubiquinone (MitoQ) over a 12-week
period and assessed tubular and glomerular function. Fibrosis
and pro-ﬁbrotic signalling pathways were determined by
immunohistochemical analysis, and mitochondria were isolated
from the kidney for functional assessment. MitoQ treatment
improvedtubularandglomerularfunctionintheIns2
+/−AkitaJ mice.
MitoQ did not have a signiﬁcant effect on plasma creatinine
levels, but decreased urinary albumin levels to the same level
as non-diabetic controls. Consistent with previous studies, renal
mitochondrial function showed no signiﬁcant change between
any of the diabetic or wild-type groups. Importantly, interstitial
ﬁbrosis and glomerular damage were signiﬁcantly reduced in the
treated animals. The pro-ﬁbrotic transcription factors phospho-
Smad2/3 and β-catenin showed a nuclear accumulation in the
Ins2
+/−AkitaJ mice, which was prevented by MitoQ treatment.
Theseresultssupportthehypothesisthatmitochondriallytargeted
therapies may be beneﬁcial in the treatment of diabetic
nephropathy. They also highlight a relatively unexplored aspect
of mitochondrial ROS signalling in the control of ﬁbrosis.
Key words: diabetes, Ins2
+/−AkitaJ mice (Akita mice), interstitial
ﬁbrosis, mitochondrial function, MitoQ, renal clearance.
INTRODUCTION
The increasing incidence of secondary complications associated
with diabetes highlights the need to improve existing treatment
regimens and preventive measures. Current data indicate that
approx. 43% of new cases of ESRDs (end-stage renal
diseases) are due to diabetes, suggesting the need for novel
therapiestoaddressdiabetes-inducedkidneydamage[1].Diabetic
nephropathy is characterized by decreased glomerular ﬁltration
rate, proteinuria, mesangial expansion, tubulointerstitial ﬁbrosis
and glomerulosclerosis [2,3].
Both Type 1 and Type 2 diabetes mellitus have complex patho-
physiologies, including insulin resistance syndrome and hyper-
glycaemia, which are associated with abnormalities in fat
oxidation and increased formation of ROS (reactive oxygen
species) and RNS (reactive nitrogen species) [4,5]. Kidney
mitochondria from STZ (streptozotocin)-induced diabetic rats
show increased superoxide production and post-translational
modiﬁcation of mitochondrial complex III [6,7]. The production
of ROS from the mitochondria has received a great deal of
attention, and it is now becoming clear it may be regulated
under physiological conditions and play an important role in
redox cell signalling. For example, it has been shown that mito-
chondrial ROS produced at complex III can activate proliferative
signalling pathways in cancer cells [8,9]. ROS-mediated
mechanisms have also been reported to lead to activation of
matrix metalloproteinases 2 and 9 via a decrease in Mn-SOD
(manganese superoxide dismutase) activity [10]. Mitochondrial
ROS production occurs at several sites in the respiratory chain,
including complexes I and III. These major sites of ROS
production both involve the low-molecular-mass redox shuttle
CoQ (coenzyme Q). Decreased levels of CoQ are associated with
increased ROS production and it is reasonable to suggest that
such conditions will result in dysregulation of mitochondrial-
dependentredoxsignalling[11].Interestingly,decreasedlevelsof
CoQ in the kidneys have been reported in the rat model of STZ-
induced diabetes [12]. As has been shown previously, the CoQ
antioxidant system can be supplemented with a mitochondria-
targeted analogue MitoQ (mitoubiquinone) [13]. This molecule
is orally bioavailable, accumulates in many tissues in the body,
including the kidney, and can protect organs from insults such
as ischaemia/reperfusion, endothelial cell dysfunction, cardiac
hypertrophy and sepsis [14–19]. We therefore hypothesized
that treatment with MitoQ could protect mitochondrial redox
signalling from hyperglycaemia-induced alterations and this
would ameliorate diabetic nephropathy.
To test the potential role of mitochondria in diabetic
nephropathy we used the genetic model of Type 1 diabetes,
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the Akita mouse (Ins2
+/−AkitaJ mice). Akita mice develop
hyperglycaemiabecausetheAchainofmatureinsulinismutated,
resulting in misfolding of the insulin protein [20]. Symptoms
in the heterozygous mutant mice include hyperglycaemia,
hypoinsulinaemia, polydipsia and polyuria, beginning at around
3–4 weeks of age. Akita mice undergo progressive organ
dysfunction in the kidney and retina after the onset of hypergly-
caemia, exhibiting increased proteinuria, vascular permeability,
increased apoptosis and alterations in the retina [21–23].
Mitochondria in this model show morphological changes, up-
regulation of some tricarboxylic acid cycle enzymes including
aconitase,butnomajorchangesintherespiratorychaincomplexes
or respiratory function [24,25]. In the present study we found
increased proteinuria and tubulointerstitial ﬁbrosis in the Akita
mice at 26 weeks of age, providing a relevant model for testing
the protective properties of MitoQ on mitochondrial redox
signalling.
EXPERIMENTAL
Animals and treatments
Male Ins2
+/−AkitaJ and wild-type (C57BL/6) mice (4–8 weeks old)
wereobtainedfromJacksonLaboratory(BarHarbor,ME,U.S.A.)
and were maintained on laboratory chow and water ad libitum
until they were 14 weeks old. Blood glucose levels (using an
Accu-Chek Advantage blood glucose meter; Roche Diagnostics)
andbodyweightweredeterminedpriortothetreatmentandevery
month thereafter. At 14 weeks of age MitoQ was administered
to the experimental animals in the drinking water provided
in dark bottles at the doses shown in Table 1 for 12 weeks.
Assignment of animals for MitoQ treatment was made in such
a way that the animals of different experimental groups were
age-matched during the study. Both wild-type and Ins2
+/−AkitaJ
mice were provided with unrestricted access to food. The activity
level, body weight and blood glucose level of the animals
were monitored constantly. The volume of water consumed was
measured and used to calculate the drug dosage received by the
animals. The Ins2
+/−AkitaJ mice consumed approx. 5-fold more
water compared with the wild-type animals, and for this reason
the concentration of MitoQ in the drinking water was adjusted to
achieve approximately the same body-weight-independent dose.
However, considerable variation occurred in the amount of water
intake in the Ins2
+/−AkitaJ mice, which resulted in some variation
in the amount of MitoQ consumption in individual animals
(Table 1). After feeding for 12 weeks, the experimental animals
werekilledunderisoﬂuraneanaesthesia(2%isoﬂuranein100%
oxygen using an isoﬂurane vaporizer) and blood and tissues were
collected. Whole blood collected in heparinized tubes by cardiac
puncturewascentrifugedat1000 gfor5 mintocollecttheplasma.
Tissues collected were ﬁxed in 4% (w/v) paraformaldehyde,
ﬂash-frozen in liquid nitrogen, or processed for the isolation
of mitochondria. The plasma creatinine measurements were
performed using ESI (electrospray ionization)–MS [26]. All the
procedures were performed in accordance with recommendations
in The Guide for the Care and Use of Laboratory Animals, and
approved by the Institutional Animal Care and Use Committee at
University of Alabama at Birmingham.
Renal imaging
Imaging of 99mTc (technetium-99m)–MAG3 (mercaptoacetyl-
triglycine) and 99mTc–DTPA (diethylenetriaminepenta-acetic
acid) in the experimental animals was performed on separate
days,asdescribedpreviously[27],todeterminetherenalfunction
at 1 week before killing (25 weeks of age). Brieﬂy, mice were
hydrated 30 min prior to the imaging with an injection of 0.5 ml
of sterile saline (intraperitoneally). After 30 min, three mice
were placed on a parallel-hole collimator, linked to an Anger
gamma camera (420/550 Mobile Radioisotope Gamma camera;
Technicare) with a central isoﬂurane anaesthesia delivery system.
Whole-body imaging of the mice was initiated with a tail-
vein bolus injection of either 99mTc-MAG3 or 99mTc-DTPA
(Birmingham Nuclear Pharmacy), at 1.0 mCi per 25 g of body
weight, and dynamic acquisition was performed using Numa
Station. Real-time planar images were collected for 20 min, with
125 frames collected at one frame every 10 s. Images were
analysed using a modiﬁed version of the NIH Image software
(NucMed-Image, Mark D. Wittry, St. Louis University, St. Louis,
MO, U.S.A.). ROIs (regions of interest) were drawn separately
around the whole body, left kidney, right kidney, urinary bladder
and a region between the heart and left kidney (for background
correction). The total pixels and the counts per pixel in each ROI
wascalculatedandexpressedrelativetothewholebody.Usingthis
method, the amount of the tracer present in each compartment as
a percentage of the total injected dose was calculated and plotted
against time. The AUC (area under the curve) for the ﬁrst 10 min
after injection, the time taken to reach the peak tracer levels and
the peak value were calculated separately for each kidney and the
bladder.
Urine collection and estimation of urine albumin
Urine from the experimental animals was collected for 24 h
on ice using diuresis cages (Tecniplast) and the volumes were
determined. Urine albumin levels were determined using a
mouse-speciﬁc ELISA system for urine albumin (EMA3201-1;
AssayPro) and was calculated as the total amount of albumin
excreted per day.
Immunohistochemistry and electron microscopy
The renal tissues were collected and ﬁxed in 4% (w/v)
paraformaldehyde solution for 24 h at room temperature (23◦C).
Parafﬁn-embeddedtissuesweresectioned(5μm)andstainedwith
haematoxylin/eosin, Masson’s trichrome and PASR (Picric Acid
SiriusRed).ImmunoreactivitywasvisualizedusingAlexaFluor®
488 goat anti-rabbit (Invitrogen), and primary anti-β-catenin and
anti-phospho-Smad2/3 antibodies (Abcam, Millipore). Tissues
slices were blocked using goat serum and slides lacking primary
antibody were used as controls. Slides were imaged using Simple
PCI software on a Leica DMRXA2 Microscope ﬁtted with
a charge-coupled device camera (Hamamatsu). Fluorescently
stained slides were quantiﬁed based on the intensity of positive
stained nuclei. PASR- and ﬂuorescent-stained renal sections were
imaged (400× total magniﬁcation) and quantiﬁed using Image-
Proplus(MediaCybernetics).Aone-halfareafromthetransverse
sections of the kidney was selected from each sample for the
quantiﬁcation of the percentage of the ﬁbrotic area in the PASR
images. Ultra-thin resin-embedded kidney sections (90 nm thick)
weremountedontocoppergridsandimagedusingatransmission
electron microscope (model H-7650-II; Hitachi) equipped with
an AMT digital camera (Danvers) and the images were analysed
for GBM (glomerular basement membrane) thickening using the
Simple PCI software.
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Table 1 Effects of MitoQ treatment on physiological parameters in the wild-type and Ins2+/−AkitaJ animals
The values reﬂect the level of each parameter determined at the end of the study, except for the drug uptake which is shown as the average and range over the course of the 12week treatment period.
Mean values (n=8–9) were analysed by ANOVA and Newman–Keuls test and expressed (+ − S.E.M.). P  0.05 relative to the wild-type untreated (*), the wild-type MitoQ treatment group (†)o r
the Ins2+/−AkitaJ untreated group (‡).
Wild-type mice Ins2+/−AkitaJ mice
Parameter Untreated MitoQ Untreated MitoQ
Body weight (g) 26.88+ −0.73 29.31+ −1.21 22.19+ −1.03* 21.25+ −0.34†
Kidney weight/body weight (g/g) 0.0078+ −0.0004 0.007+ −0.0002 0.0103+ −0.001* 0.010+ −0.0004†
Heart weight/body weight (g/g) 0.0048+ −0.0003 0.005+ −0.0003 0.0056+ −0.001 0.005+ −0.0004
Water consumption (ml/day) 2.90+ −0.05 2.86+ −0.08 21.81+ −1.9* 17.61+ −1.5†
MitoQ (mg/kg of body weight per day) – 2.61+ −0.13 (2.34–2.79) – 4.34+ −0.32† (1.93–6.61)
Blood glucose (mg/dl) 163.56+ −17.7 173.78+ −16.3 681.78+ −82.6* 604.2+ −73.7†
HbA1c (%) 4.37+ −0.076 4.34+ −0.065 12.47+ −0.49* 10.34+ −0.35†‡
Plasma insulin (ng/ml) 0.36+ −0.052 0.45+ −0.04 0.14+ −0.17* 0.16+ −0.017†
Plasma creatinine (mg/dl) 0.099+ −0.003 0.088+ −0.01 0.094+ −0.010 0.088+ −0.009
Table 2 Effect of MitoQ treatment on mitochondrial activities
The respiratory capacity of the mitochondria isolated from the kidneys of experimental animals was determined polarographically as described in the Experimental section. Activities of mitochondrial
respiratory chain complex I, complex IV and citrate synthase were measured using isolated mitochondria from the kidney. Results are means+ −S.E.M. (n=8, per group). Statistical comparisons
were performed with ANOVA and Newman–Keuls test.
Wild-type mice Ins2+/−AkitaJ mice
Actvity Untreated MitoQ Untreated MitoQ
State 4 (nmol O2/min per mg) 61.58+ −5.27 64.40+ −3.25 68.24+ −3.51 71.50+ −3.33
State 3 (nmol O2/min per mg) 111.49+ −14.07 126.99+ −6.01 142.54+ −7.85 151.75+ −7.85
RCR 1.75+ −0.11 1.98+ −0.05 2.09+ −0.04 2.11+ −0.05
Complex I (nmol/min per mg) 484+ −42 500+ −38 464+ −21 478+ −35
Complex IV (k/s per mg) 54.2+ −7.4 45+ −7.6 57+ −7.3 53.7+ −3.0
Citrate synthase (nmol/min per mg) 0.167+ −0.012 0.165+ −0.011 0.165+ −0.012 0.158+ −0.007
Mitochondrial isolation and respiration
Mitochondriawereisolatedfromthekidneywithhomogenization
followed by multiple centrifugations at 700 g, 7800 g and
10000 g in ice-cold isolation buffer containing 50 mM Tris/HCl,
pH 7.4, 250 mM sucrose, 5 mM EDTA and protease inhibitors
as described previously [28]. Respiratory capacity of isolated
mitochondriawasassessedinaHansatechOxygraphinmitochon-
drial respiration medium (2.5 mM Hepes, pH 7.4, 120 mM KCl,
5m M K H 2PO4, 1 mM EGTA, 10.7 mM MgCl2 and 2.5 mM
sucrose) and 5 mM succinate/0.5 mM ADP at 37◦C.
Measurement of mitochondrial complex and citrate synthase
activities
Mitochondria isolated from kidney were frozen in liquid nitrogen
andstoredat−80◦C.Immediatelybeforetheassay,mitochondrial
samples were suspended in 0.1M phosphate buffer with 0.2%
lauryl maltiside (or for complex I in 0.025M phosphate buffer
only), subjected to three freeze–thaw cycles in liquid nitrogen
and vortex-mixed to ensure mitochondrial lysis. Mitochondrial
complex I activity was measured spectrophotometrically (using
a Beckman Coulter Spectrophotometer) as the rotenone-sensitive
rate of NADH oxidation, and complex IV activity was measured
as the cyanide-sensitive pseudo-ﬁrst-order rate constant for the
oxidation of reduced cytochrome c [29]. Mitochondrial citrate
synthase activity was measured by the reduction of DTNB [5,5
 -
dithiobis-(2-nitrobenzoic acid)] by citrate synthase and using the
coupled reaction with acetyl-CoA and oxaloacetate [29].
Statistical analysis
All results are expressed as means+ −S.E.M. An unpaired
Student’sttestwasusedtocomparethecontrolandtreatedgroups.
ANOVA and the Newman–Keuls test were used to compare the
mean values for multiple group comparisons. All values were
considered signiﬁcant at P 0.05.
RESULTS
MitoQ treatment did not alter the glycaemic status of diabetic
animals
All the animals irrespective of the treatment group gained weight
at similar rates, but wild-type mice were 20–25% heavier than
the age-matched Ins2
+/−AkitaJ mice and this was unaltered by
drug treatment (Table 1). Ins2
+/−AkitaJ mice at 12 weeks of age
were hyperglycaemic, consistent with previous reports [22,30],
and this was not affected by MitoQ treatment. In addition, the
plasma insulin levels of these animals remained unchanged with
drug treatment at the end of the study (Table 1). However,
glycatedhaemoglobinlevelsinMitoQ-treatedIns2
+/−AkitaJ animals
demonstratedamarginalbutstatisticallysigniﬁcantdecreaseafter
12 weeks of treatment (Table 1).
Succinate-dependent respiration of isolated mitochondria from
the kidney was assessed polarographically for all groups. As
reported by others [24] no signiﬁcant change between any of the
groupswasfoundforState3or4respirationrates(Table2).RCRs
(respiratorycontrolratios;State3/State4)didnotchangebetween
any groups (Table 2). Activities of mitochondrial respiratory
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Figure 1 MitoQ treatment prevents renal tubular dysfunction in Ins2+/−AkitaJ mice as determined by 99mTc–MAG3 clearance
(A) Real-time imagesofthemiceafter thetail-vein injection oftheradioactivetracer 99mTc–MAG3.Uponinjection thetracer accumulatesandthen clearsoutofthekidneyto theurinarybladder.The
presence of radioactivity is detected using a gamma camera. (B) Means+ −S.E.M. (n=5–8) of the original traces of the dye accumulation and clearance proﬁle in the kidneys relative to the amount
of the dye present in the whole body from non-diabetic wild-type (WT) and diabetic Ins2+/−AkitaJ mice (Akita), with (MitoQ) or without (Ctrl) MitoQ treatment. Statistical comparison was performed
with ANOVA and the Newman–Keuls test. #P  0.05 relative to the MitoQ-treated Ins2+/−AkitaJ group.
complex I and complex IV from kidney did not show any
signiﬁcant change between the experimental animals with or
without MitoQ treatment.
MitoQ prevents diabetes-induced tubular dysfunction
Assessmentofrenalfunctioninvivowasperformedbymeasuring
theclearanceof99mTc–MAG3.Thisisasensitiveandextensively
usedmethodforthedeterminationoftubularfunction[27,32].The
tracer accumulates in the kidneys >55% with the ﬁrst pass and is
then cleared without any signiﬁcant reabsorption. An increase in
thetimetakenforclearancecanbeconsideredtobeindicativeofa
decreaseinrenalfunction.Representativeimagesfromthegamma
camera at 100 s after injection of the 99mTc–MAG3 are shown in
Figure 1(A) (left-hand panel), showing the initial accumulation
in the kidney followed by a rapid clearance to the bladder over
the next 6–8 min. MitoQ treatment had no signiﬁcant impact
on this process in wild-type animals. In contrast, the tracer was
retainedinthekidneyoverapprox.15 minintheIns2
+/−AkitaJ mice,
consistent with a profound tubular dysfunction (Figure 1A, right-
hand panel). MitoQ treatment of the Ins2
+/−AkitaJ mice resulted in
a rate of 99mTc–MAG3 clearance similar to control wild-type
animals (Figure 1B).
Further analysis of the 99mTc–MAG3 renal clearance proﬁle
was performed by determining: (i) AUCs up to 10 min from the
time of injection; (ii) the peak value of the percentage injected
dose; and (iii) time taken to reach peak accumulation. AUC
provides an assessment of the overall performance of the kidney
and it correlates inversely with the rate of clearance of the tracer.
The AUC was much greater for 99mTc–MAG3 renal clearance
for the Ins2
+/−AkitaJ mice compared with the wild-type controls,
consistent with renal dysfunction (Figure 2A) and was restored to
normal values in response to MitoQ treatment. The time to reach
peak value for the 99mTc–MAG3 renal clearance proﬁle was
dependent upon the relative rate of accumulation of the tracer
in the kidney compared with the rate of clearance to the
bladder and was increased in the Ins2
+/−AkitaJ mice (Figure 2B).
MitoQ treatment prevented this renal functional defect in the
diabetic animals (Figure 2B). Interestingly, there were no signi-
ﬁcant differences in the maximal level of accumulation of the
tracer under any condition, suggesting that renal dysfunction is
associated primarily with impaired tubular ﬁltration (Figure 2C).
In support of this conclusion accumulation of 99mTc–MAG3 in
c   The Authors Journal compilation c   2010 Biochemical Society © 2010 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.MitoQ prevents diabetic nephropathy in Akita mice 13
Figure 2 Protection of renal tubular function by MitoQ in Ins2+/−AkitaJ mice
(A)Quantiﬁcationofthe99mTc–MAG3renalclearanceproﬁlecalculatedastheAUCfromindividualanimalsupto600sfromthetraceradministration.(B)Timetakentoreachthepeakaccumulation
and (C) peak tracer accumulation value of the 99mTc–MAG3 renal clearance analysis. (D) Accumulation of the tracer in the urinary bladder was also determined as the AUC up to 10min from the
time of injection. Results are means+ −S.E.M. (n=5–8). Statistical comparison was performed with ANOVA and the Newman–Keuls test. #P  0.05.
the bladder was delayed in the Ins2
+/−AkitaJ and restored by MitoQ
(Figure 2D).
MitoQ-dependent protection of glomerular function of diabetic
kidneys
Using the 99mTc–DTPA clearance assay for glomerular function
[33], our observations suggest that MitoQ does not change the
proﬁle for uptake and clearance in the wild-type animals. In
the case of the Ins2
+/−AkitaJ mice there was signiﬁcant retention
of the tracer, which was restored to control levels by MitoQ
(Figures 3A and 3B). MitoQ treatment prevented development of
glomerular dysfunction in the diabetic animals, and the treatment
did not affect the glomerular function in wild-type animals.
Using the same method of analysis established for 99mTc–
MAG3 to the 99mTc–DTPA clearance proﬁle, we found that the
AUC for the tracer was increased in the Ins2
+/−AkitaJ mice and
restored to control levels by MitoQ (Figure 4A). In the untreated
experimental groups the time taken to reach the peak value was
signiﬁcantly higher for Ins2
+/−AkitaJ mice compared with the wild-
type animals. MitoQ treatment signiﬁcantly decreases 99mTc–
DTPA peak accumulation in Ins2
+/−AkitaJ mice (Figure 4C), but
did not modify the time taken to attain the peak (Figure 4B),
implyingthatthetraceraccumulatesatadecreasedrate.However,
bladder accumulation of 99mTc–DTPA was not altered in any
of the experimental groups (Figure 4D). Albuminuria is a
reliable marker of renal involvement in diabetic kidney disease.
MitoQ treatment attenuated urine albumin excretion in diabetic
animals(Figure5A).Massspectrometricdeterminationofplasma
creatinine [26] did not show any signiﬁcant change among the
experimental groups at 26 weeks (Table 1).
Effects of MitoQ treatment on renal tissue morphology
in Ins2+/−AkitaJ mice
Histological analysis of the kidney tissue sections demonstrated
the typical pathological changes of diabetic nephropathy in
Ins2
+/−AkitaJ micecomparedwiththewild-typeanimals(Figure5B,
left panels). As shown in the lower right-hand panel of
Figure 5(B), the renal histology of the MitoQ-treated Ins2
+/−AkitaJ
mice resembled that of the wild-type controls without any
indication of diabetes-induced kidney damage. No histological
evidence of toxicity was observed in association with MitoQ
treatment in wild-type animals. GBM thickening is a potential
causeofdecreasedglomerularﬁltrationindiabetickidneydisease
[34]. Transmission electron microscopy demonstrated increased
GBM thickness in Ins2
+/−AkitaJ mice compared with wild-type
controls (Figures 6A and 6B). MitoQ treatment prevented GBM
thickening in diabetic mice and did not have any effect on the
wild-type animals.
Chronic hyperglycaemia associated with diabetes induces
ﬁbrotic changes mediated by inﬂammatory cytokines, growth
factors, such as TGFβ (transforming growth factor β)a n dW n t /
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Figure 3 MitoQ protects against diabetic glomerular dysfunction in Ins2+/−AkitaJ mice as determined by the 99mTc-DTPA clearance
(A) Representative real-time images of the whole animal at various time points during the study are shown. (B) Means+ −S.E.M. (n=4–6) of the proﬁles demonstrating the uptake and clearance
phases of the 99mTc–DTPA radioactive tracer in the right kidney after injection through the tail vein by analysing the real-time images from non-diabetic wild-type (WT) and diabetic Ins2+/−AkitaJ
mice (Akita), with (MitoQ) or without (Ctrl) MitoQ treatment.
β-catenin signalling. Staining of diabetic renal tissues with
Masson’s Trichrome (Figure 7A) and quantiﬁcation of PASR
staining (Figure 7B) showed the tubulointerstitial ﬁbrosis in
Ins2
+/−AkitaJ mice was similar to that observed in diabetic patients
with kidney disease [35]. Treatment with MitoQ for 12 weeks
signiﬁcantly decreased interstitial ﬁbrosis in the diabetic animals.
Investigation of the possible mediators of the hyperglycaemia-
inducedﬁbroticresponsesuggestedtheinvolvementofTGFβ and
Wnt signalling. Localization of phospho-Smad2/3 (Figure 8)
and β-catenin in the nuclei (Figure 9) of diabetic tissues is
consistent with activation of these signalling pathways in the
Ins2
+/−AkitaJ mice.
DISCUSSION
Diabetic kidney disease is a chronic pathological condition that
has a limited number of effective therapies [36,37]. Indirect
approachesofstrictglycaemiccontrolandmaintenanceofnormal
blood pressure delay the progression of the disease [36,37].
Despite these measures, a signiﬁcant number of cases progress
to diabetic nephropathy, which is characterized histologically by
tubulointerstitial ﬁbrosis, diffuse or nodular glomerulosclerosis
and variable degrees of hyaline arteriolosclerosis. Mechanisms
including changes in glomerular haemodynamics due to altered
vascular resistance, inﬂammation and augmented formation of
AGEs (advanced glycation end-products) have been suggested
in the pathogenesis [35]. Increased synthesis of TGFβ and an
abnormalrenin–angiotensinsystemhavealsobeenproposedtobe
involvedintheprogressionofdiabeticnephropathy[36].Changes
in the β-catenin signalling pathway are now also thought to play
a pro-ﬁbrotic role in a number of pathologies including diabetes
[38]. Several studies have shown that altered mitochondrial
functionoccursinthedevelopmentofdiabetickidneydisease,but
the contribution to the pathophysiological changes, particularly
ﬁbrosis, associated with diabetes is not clear [39].
In vitro and in vivo studies have shown that overexpression
of mitochondrial antioxidant enzymes in renal proximal tubular
cells and in the retina protect against oxidant-induced damage
in experimental hyperglycaemia [40,41]. Evidence from the
cancer and cardiovascular ﬁelds suggest that oxidant production
from the mitochondria appears to play a role in the cell
signalling associated with tissue remodelling, proliferation
and angiogenesis [9,42]. For these reasons we hypothesized
that a mitochondrially targeted antioxidant that can modulate
the production of ROS from enzymes associated with CoQ
may have beneﬁcial effects in diabetic nephropathy. Of
the potential compounds available the ubiquinone analogue
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Figure 4 Preservation of glomerular function by MitoQ in Ins2+/−AkitaJ mice
(A) Quantiﬁcation of the 99mTc–DTPA renal clearance proﬁle calculated as the AUC from individual animals up to 10min from the tracer administration. (B) Time taken to reach peak accumula-
tion of tracer in the kidney. (C) The amount of the radioactive tracer at the time of peak accumulation in the right kidney after 99mTc–DTPA injection was calculated. (D) The peak accumulation
values of the DTPA clearance analysis were determined from the proﬁle curve plotted with the percentage injected dose against time. Results are means+ −S.E.M (n=4–6). Statistical comparison
was performed with ANOVA and the Newman–Keuls test. #P  0.05.
MitoQ has attracted particular interest since it is orally
bioavailable, has low toxicity and reaches concentrations of 200–
700 pmol per g of wet weight in the tissue of a number of organs,
including the kidney [43]. For example, in animal models MitoQ
treatment has been shown to prevent ischaemia/reperfusion-
induced cardiac dysfunction [17,44], decrease inﬂammation in
a LPS (lipopolysaccharide)–peptidoglycan-induced rat sepsis
model [14] and to protect the heart against doxorubicin toxicity
[15]. It has been shown that MitoQ treatment was also protective
against endothelial cell dysfunction in vitro and in vivo [19,45].
Importantly, MitoQ has been used in Phase I and Phase II
clinical trials for Parkinson’s disease and hepatitis-C-induced
liver damage, and is well-tolerated in human and animal subjects
[46,47].
In the present study the Ins2
+/−AkitaJ mice were selected as a
model of Type 1 diabetes to test the potential beneﬁts of MitoQ
therapy. This model develops insulin resistance over time and has
many of the characteristics of chronic hyperglycaemia associated
with both Type 1 and 2 diabetes [22,25]. Ins2
+/−AkitaJ mice have
been used in several studies and are reported to have increased
oxidativestressinthekidney[30,48]andabnormalmitochondrial
morphology in the diabetic kidney, but no change in volume
density and number [24]. Decreased levels of SOD1 and SOD3,
but not SOD2 exacerbate diabetic nephropathy in these mice and
the disease progression was prevented using the SOD mimetic
tempol, supporting a role for the dysregulation of ROS in diabetic
nephropathy [49]. Recent studies have reported the attenuation of
diabetickidneydiseaseusingrecombinantangiotensin-converting
enzymetreatment[50]andcyclo-oxygenase2inhibitortreatment,
which are both pathways known to generate increased levels of
ROS [51].
Oral MitoQ treatment was sustained over a period of 11–
12 weeks in wild-type control and Ins2
+/−AkitaJ mice, after which
a number of end-points relevant to diabetes were determined.
The pharmacological delivery of MitoQ was adjusted based on
the water intake of the animals for a body-weight-independent
dose, due to substantially increased water consumption by the
Ins2
+/−AkitaJ mice. However, when corrected for body weight
thecontrolmicewereheavier,resultinginaslightlylowerdoseof
MitoQ for the controls. MitoQ treatment resulted in lower HbA1c
levels in the Ins2
+/−AkitaJ mice, however the changes were modest
and unlikely to account for the prevention of renal pathology with
MitoQ treatment.
Histochemical staining of the kidney tissue sections revealed
mesangial expansion and tubulointerstitial ﬁbrosis. MitoQ
treatment signiﬁcantly prevented these tissue pathologies
associated with diabetic nephropathy. Assessment of kidney
function required the use of sensitive non-toxic and minimally
invasive techniques, and for this we used 99mTc–MAG3 and
99mTc–DTPA [32]. Increased clearance of these tracers was
evident for MitoQ-treated Ins2
+/−AkitaJ mice, consistent with
MitoQ-mediated protection of renal tubular and glomerular
function. As demonstrated in the present study, and by others
[34], Ins2
+/−AkitaJ mice have pronounced GBM thickening in
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Figure 5 MitoQ treatment decreases albuminuria in diabetic Ins2+/−AkitaJ
mice
(A) The albumin levels of the 24-h-urine samples were estimated using the mouse urine
albumin ELISA kit and the total amount of albumin excreted per day was measured. Results are
means+ −S.E.M. (n=6–8) as analysed by ANOVA and the Newman–Keuls test. #P  0.05.
(B) Renal tissue morphology in diabetic Ins2+/−AkitaJ mice was signiﬁcantly improved by oral
MitoQ treatment. Representative images of haematoxylin/eosin-stained renal sections show
signiﬁcant improvement in diabetes-induced glomerular injury in Ins2+/−AkitaJ mice.
the peripheral capillary loops, which was prevented by MitoQ
(Figure6).PreventionofGBMthickeningwithMitoQtreatmentis
consistentwiththeimprovementinglomerularclearancefunction
as assessed with 99mTc–DTPA. Although plasma creatinine
remained unchanged, the decreased urine albumin in Ins2
+/−AkitaJ
mice with MitoQ treatment also indicates that renal function
was improved. This can be explained on the basis of reports in
animal models of nephropathy that proteinuria is a more sensitive
marker of kidney disease compared with plasma creatinine
measurements [52]. Ins2
+/−AkitaJ mice demonstrated mesangial
expansion,tubulointerstitialﬁbrosisanddecreasedrenalfunction,
which closely reﬂects human diabetic nephropathy [35]. The
decreased mesangial expansion, interstitial ﬁbrosis and GBM
thickening observed in the MitoQ-treated Ins2
+/−AkitaJ animals
compared with the untreated diabetic animals suggests that the
MitoQ treatment modulates the proﬁbrotic signalling pathways in
the diabetic kidney.
Figure 6 MitoQ decreases GBM thickening in Akita mice
(A) Representative transmission electron micrographs (viewed at 6500×) of the renal tissues
demonstratingthickeningoftheGBMinAkitamicecomparedwiththewild-typecontrols.MitoQ
treatment prevented GBM thickening in Akita mice. (B). Quantiﬁcation of the GBM thickening
using Simple PCI software. The mean thickness (n=3, per group) was calculated, analysed by
ANOVA and the Newman–Keuls test and expressed (+ − S.E.M). #P  0.05.
Severalpathophysiologicalcharacteristicsofdiabetesincluding
hyperglycaemia, hypertension, mechanical stress and ROS
production can activate the expression of the proﬁbrotic
cytokine TGFβ. The signalling mediated by TGFβ occurs
by phosphorylation and nuclear translocation of Smad2/3,
resulting in the synthesis of proteins involved in extracellular
matrix accumulation [53]. Several studies have demonstrated the
stimulation of TGFβ-mediated signalling results in increased
productionandaccumulationofextracellularmatrixproteins,and
activation of protease inhibitors. In addition, TGFβ induces its
ownsynthesisandstimulatestheproliferationoftubulointerstitial
ﬁbroblasts, resulting in the ampliﬁcation of the ﬁbrotic response.
Demonstration of tubulointerstitial ﬁbrosis (Figure 7), and
increased phosphorylation and nuclear translocation of Smad2/3
(Figure 8A and 8B), conﬁrms the activation of TGFβ-mediated
proﬁbroticsignallinginthediabeticanimals.Interestingly,MitoQ
inhibited the nuclear translocation of phospho-Smad2/3. In
addition, the Wnt/β-catenin signalling has been shown to play a
crucial role as a proﬁbrotic signal in a number of pathologies, and
recently has been implicated in diabetes-induced retinal ﬁbrosis
[38]. The majority of Wnt/β-catenin studies have been in the
c   The Authors Journal compilation c   2010 Biochemical Society © 2010 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.MitoQ prevents diabetic nephropathy in Akita mice 17
Figure 7 MitoQ treatment decreases diabetes-induced renal interstitial
ﬁbrosis
(A) Parafﬁn-embedded sections were prepared from paraformaldehyde-ﬁxed tissues and
stained with Masson’s Trichrome for tissue collagen and imaged using Simple PCI software.
(B) PASR-stained renal sections were imaged and quantiﬁed using Image-Pro plus. Average
ﬁbrotic area values were determined from one-half of the kidney cross-section (n=8–9 per
group), means values were analysed by ANOVA and the Newman–Keuls test test and expressed
(+ − S.E.M). #P  0.05.
ﬁelds of embryogenesis and cancer, and it has shown to have an
important role in the EMT (epithelial-to-mesenchymal transition)
[54]. A number of studies have implicated EMT as a mechanism
of ﬁbrotic deposition in a range of insults including diabetes
[54]. Wnt/β-catenin has been shown to exert different effects
in the kidney, e.g. protective effects on mesangial cells and yet
proﬁbrotic effects in tubular cells [55,56]. The Wnt/β-catenin
pathwayisredox-sensitiveandisthereforepotentiallysensitiveto
mitochondrialoxidants[57].Insupportofthisargumentwefound
that MitoQ suppressed β-catenin translocation to the nucleus
(Figure 9).
Since MitoQ was administered orally it is possible it may exert
its effects in several different cell types and for this reason the
mechanism(s) of action will require further investigation. There
are, however, several possibilities which can be suggested on
the basis of previous studies with this compound. In isolated
Figure 8 MitoQ treatment inhibits phospho-Smad2/3-mediated signalling
in the diabetic kidney
(A) Parafﬁn-embedded sections were prepared from paraformaldehyde-ﬁxed tissues and
stained with anti-phopho-Smad2/3 antibody linked to Alexa Fluor® 488 (green); the nuclei
were stained with DAPI (4 ,6-diamidino-2-phenylindole; blue) . Sections were imaged using
Simple PCI software. (B) Images were quantiﬁed for phospho-Smad2/3 localization in the
nucleus using Simple PCI software. Mean green intensities (n=6, per group) were calculated,
analysed by ANOVA and the Newman–Keuls test and expressed (+ − S.E.M). #P  0.05.
mitochondria it has been shown that MitoQ can be converted
into mitoubiquinol by complex II, but is not readily oxidized by
complex III or reduced by complex I [13]. This suggests it would
potentially change the redox balance and change mitochondrial
redox signalling, since this is an important site of superoxide
and hydrogen peroxide formation in the mitochondrion. Since
mitochondrial respiratory chain proteins are not signiﬁcantly
altered in the kidney mitochondria from the Akita mice [24], and
in the present study MitoQ treatment did not alter the respiratory
capacity of mitochondria, it is unlikely that protection of these
proteins is important in the mechanism leading to prevention of
diabetic nephropathy.
In conclusion, we report that the Type 1 diabetic model
of Ins2
+/−AkitaJ mice display both renal tubular and glomerular
defects associated with diabetes, which are attenuated by oral
administration of MitoQ. Histological evidence suggests that
the improvement of renal function in MitoQ-treated Ins2
+/−AkitaJ
mice correlates with attenuation of tubulointerstitial ﬁbrosis.
Diabetes-induced alterations in the cellular redox status could
have an impact upon the redox signalling pathways that control
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Figure9 MitoQtreatmentdecreasesβ-cateninnucleartranslocationinthe
Ins2+/−AkitaJ kidney
(A) Representative images demonstrating translocation of activated β-catenin in the
nucleus. Immunohistochemical analysis showed increased β-catenin in the nucleus of
diabetic mice when probed with an anti-β-catenin antibody linked to Alexa Fluor® 488
(green) and DAPI (4 ,6-diamidino-2-phenylindole) counter-stain (blue). (B) Quantiﬁcation of
immunohistochemical images showed a signiﬁcant increase in nuclear β-catenin intensity in
diabetic mice compared with the wild-type controls, which was signiﬁcantly decreased with
MitoQ treatment (n=6). Mean green intensities (n=6, per group) were calculated, analysed
by ANOVA and the Newman–Keuls test and expressed (+ −S.E.M). #P  0.05.
tissue remodelling, which maybe ameliorated by MitoQ. Taken
together these ﬁndings support the hypothesis that dysregulation
of mitochondrial signalling plays a key role in diabetic kidney
disease.
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